NT
Intellia Therapeutics, Inc.
NTLA · NASDAQ
$11.74 -2.98% (-$0.36)
1M -2.89%
Market Cap $1.64B
P/E Ratio -
Div. Yield -
ROE 57.79%
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/B 2.25x
P/S 27.57x
EV/EBITDA N/A
Growth
49 /100
Stable Book val. growth 18.40%
Rev. growth 9.09%
FCF growth N/A
Profitability
0 /100
Weak Net margin 672.16%
Op. margin 711.66%
FCF margin 783.30%
Quality
1 /100
Poor ROE 57.79%
ROA 46.66%
Asset turnover 0.07x
Debt
100 /100
Low Current ratio 6.65x
Debt/Equity 0.10x
Net debt/EBITDA N/A
Stability
33 /100
Unstable Rev. volatility 45.00%
EPS volatility 12.29%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NTLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Leonard
Employees
377
Headquarters
Cambridge
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report